{"classes":[{"categories":[{"measurements":[{"comment":"insufficient number of participants with events to calculate","groupId":"OG004","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"description":"Duration of response of RMC-4630 and cobimetinib or RMC-4630 and osimertinib per RECIST v1.1","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received intermittent dose of RMC-4630 80 mg or 140 mg on D1 and D4 or on D1 and D2 of a 28-day cycle and daily dose of Cobimetinib 20 mg or 40 mg from D1 through D21 and then 7 days off Cobimetinib from D22 to D28 of a 28-day cycle.","id":"OG000","title":"Intermittent RMC-4630 (D1D4 or D1D2) + Daily Cobimetinib (QD21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and intermittent dose of Cobimetinib 40 mg or 60 mg on D1 and D2 of a 28-day cycle.","id":"OG001","title":"Intermittent RMC-4630 (D1D2) + Intermittent Cobimetinib (D1D2)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.","id":"OG002","title":"Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.","id":"OG003","title":"Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.","id":"OG004","title":"Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.","id":"OG005","title":"Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2"},{"description":"Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.","id":"OG006","title":"Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.","id":"OG007","title":"Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)"}],"paramType":"MEDIAN","populationDescription":"There were insufficient number of participants with events to calculate.","reportingStatus":"POSTED","timeFrame":"Response assessment occurs from the start of intervention until the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"day(s)"}